SinoMab BioScienceのボラティリティ
SinoMab BioScienceのボラティリティは何ですか。
SinoMab BioScience Limitedのボラティリティは9.48%です。
ボラティリティの定義は何ですか。
ボラティリティまたは平均真の範囲パーセント（ATRP14）は、終値のパーセンテージとして表されるATRです。
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
HKSEのセクタHealth Careにおけるボラティリティの企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似のボラティリティ
- American National Banksharesのボラティリティは9.47%です。
- Safestore plcのボラティリティは9.47%です。
- Third Point Offshore Investorsのボラティリティは9.47%です。
- Liberty Goldのボラティリティは9.47%です。
- China Kingstone Miningのボラティリティは9.47%です。
- Passage Bio Incのボラティリティは9.47%です。
- SinoMab BioScienceのボラティリティは9.48%です。
- Nevada King Goldのボラティリティは9.49%です。
- Great Northern Mineralsのボラティリティは9.49%です。
- GraniteShares 3x Short BAE Systems Daily ETCのボラティリティは9.49%です。
- Canopy Growthのボラティリティは9.50%です。
- Blend Labsのボラティリティは9.50%です。
- Celaminのボラティリティは9.50%です。